PMID- 7791076
OWN - NLM
STAT- MEDLINE
DCOM- 19950721
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 273
IP  - 3
DP  - 1995 Jun
TI  - Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by 
      the interaction between serotonin and gamma-aminobutyric acid in the substantia 
      nigra.
PG  - 1063-70
AB  - The effects of the amphetamine analog, 3,4-methylenedioxymethamphetamine (MDMA) 
      were compared to the effects of d-amphetamine on the in vivo release of dopamine 
      and gamma-aminobutyric acid (GABA) in the striatum and substantia nigra. The 
      brain region-dependent role of the 5-HT2 receptors in the striatum and substantia 
      nigra in regulating MDMA-induced dopamine and GABA release also was studied. 
      Changes in the extracellular concentration of dopamine, 5-HT and GABA were 
      measured simultaneously in the awake rat by in vivo microdialysis. The increase 
      in striatal dopamine produced by systemic administration of MDMA was attenuated 
      by infusion of TTX into the striatum. Infusion of the 5-HT2A/2C antagonist 
      ritanserin into the striatum or the ipsilateral substantia nigra also 
      significantly attenuated MDMA-induced dopamine release in the striatum. At the 
      doses used in this study, MDMA but not d-amphetamine increased the extracellular 
      concentrations of 5-HT and decreased GABA efflux in the substantia nigra. The 
      ability of MDMA to decrease nigral GABA efflux also was blocked by the local 
      infusion of ritanserin into either the substantia nigra or the striatum. Overall, 
      these data provide evidence that MDMA increases dopamine release partly through 
      an impulse-mediated mechanism. Furthermore, this increase in striatal dopamine 
      efflux produced by MDMA is regulated, in part, by 5-HT2A/2C receptors in the 
      striatum and the substantia nigra and ultimately by GABAergic input into the 
      substantia nigra.
FAU - Yamamoto, B K
AU  - Yamamoto BK
AD  - Department of Psychiatry, Case Western Reserve University School of Medicine, 
      Cleveland, Ohio, USA.
FAU - Nash, J F
AU  - Nash JF
FAU - Gudelsky, G A
AU  - Gudelsky GA
LA  - eng
GR  - DA07427/DA/NIDA NIH HHS/United States
GR  - DA07606/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 333DO1RDJY (Serotonin)
RN  - 4368-28-9 (Tetrodotoxin)
RN  - 56-12-2 (gamma-Aminobutyric Acid)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - TZ47U051FI (Dextroamphetamine)
SB  - IM
MH  - Animals
MH  - Corpus Striatum/*drug effects/metabolism
MH  - Dextroamphetamine/pharmacology
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serotonin/*metabolism
MH  - Substantia Nigra/*metabolism
MH  - Tetrodotoxin/pharmacology
MH  - gamma-Aminobutyric Acid/*metabolism
EDAT- 1995/06/01 00:00
MHDA- 1995/06/01 00:01
CRDT- 1995/06/01 00:00
PHST- 1995/06/01 00:00 [pubmed]
PHST- 1995/06/01 00:01 [medline]
PHST- 1995/06/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1995 Jun;273(3):1063-70.